Latest Pharma Insights
More Is Better? UK Crowdfunding Platform Selects First Firms
Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.
Scrip - September 20, 2017
Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.
Scrip - September 20, 2017
Number To Know…63 million
Emergent BioSolutions has won a $63m contract to develop an antidote spray device treating known or suspected acute cyanide poisoning.
Medtech Insight - September 20, 2017
Emergent BioSolutions has won a $63m contract to develop an antidote spray device treating known or suspected acute cyanide poisoning.
Medtech Insight - September 20, 2017
Refocused Novo Nordisk Says On 'Road To Recovery' After Traumatic 2016
Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now...
Scrip - September 20, 2017
Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now...
Scrip - September 20, 2017
Expanded IMPACT For GSK Respiratory Business From New Trelegy Data
Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta...
Scrip - September 20, 2017
Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta...
Scrip - September 20, 2017
EU Moves To RATIFY Novartis' Rydapt for AML
Rydapt represents the first major development in targeted acute myeloid leukaemia treatment in more than 25 years as Novartis plots...
Scrip - September 20, 2017
Rydapt represents the first major development in targeted acute myeloid leukaemia treatment in more than 25 years as Novartis plots...
Scrip - September 20, 2017
Unsuccessful IPOs
Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences...
IN VIVO - September 20, 2017
Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences...
IN VIVO - September 20, 2017
Amazon Versus Biotech: How The IPO Class Of '97 Worked Out
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16...
IN VIVO - September 20, 2017
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16...
IN VIVO - September 20, 2017
AbClon Shines On Korean Debut Amid Robust Investor Interest
AbClon has made a strong debut on the Kosdaq market with investors backing the innovative antibody drug firm in a...
Scrip - September 20, 2017
AbClon has made a strong debut on the Kosdaq market with investors backing the innovative antibody drug firm in a...
Scrip - September 20, 2017
UK’s NICE Backs BMS's Opdivo In Lung Cancer, But Only Via CDF With Price Cut
UK HTA body NICE has decided to make Bristol-Myers Squibb's PD-1 inhibitor Opdivo available for non-small-cell lung cancer, but only...
The Pink Sheet - September 20, 2017
UK HTA body NICE has decided to make Bristol-Myers Squibb's PD-1 inhibitor Opdivo available for non-small-cell lung cancer, but only...
The Pink Sheet - September 20, 2017
European CHMP Opinions And MAA Updates
A monthly-updated listing of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization...
The Pink Sheet - September 20, 2017
A monthly-updated listing of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization...
The Pink Sheet - September 20, 2017
Real-World Evidence Requires 'Leap Of Faith' For Industry, FDA – Gottlieb
US FDA Commissioner says agency will soon offer more clarity on using real-world evidence in drug development, but notes industry...
The Pink Sheet - September 20, 2017
US FDA Commissioner says agency will soon offer more clarity on using real-world evidence in drug development, but notes industry...
The Pink Sheet - September 20, 2017
US FDA's Benefit/Risk Framework Gets High Marks But Could Be Improved
Agency summaries contained in reviews of novel drugs and biologics are useful and informative but difficult to find, and their...
The Pink Sheet - September 20, 2017
Agency summaries contained in reviews of novel drugs and biologics are useful and informative but difficult to find, and their...
The Pink Sheet - September 20, 2017
More Is Better? UK Crowdfunding Platform Selects First Firms
Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.
Scrip - September 20, 2017
Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.
Scrip - September 20, 2017
Refocused Novo Nordisk Says On 'Road To Recovery' After Traumatic 2016
Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now...
Scrip - September 20, 2017
Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now...
Scrip - September 20, 2017
Expanded IMPACT For GSK Respiratory Business From New Trelegy Data
Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta...
Scrip - September 20, 2017
Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta...
Scrip - September 20, 2017
EU Moves To RATIFY Novartis' Rydapt for AML
Rydapt represents the first major development in targeted acute myeloid leukaemia treatment in more than 25 years as Novartis plots...
Scrip - September 20, 2017
Rydapt represents the first major development in targeted acute myeloid leukaemia treatment in more than 25 years as Novartis plots...
Scrip - September 20, 2017
AbClon Shines On Korean Debut Amid Robust Investor Interest
AbClon has made a strong debut on the Kosdaq market with investors backing the innovative antibody drug firm in a...
Scrip - September 20, 2017
AbClon has made a strong debut on the Kosdaq market with investors backing the innovative antibody drug firm in a...
Scrip - September 20, 2017
UK’s NICE Backs BMS's Opdivo In Lung Cancer, But Only Via CDF With Price Cut
UK HTA body NICE has decided to make Bristol-Myers Squibb's PD-1 inhibitor Opdivo available for non-small-cell lung cancer, but only...
The Pink Sheet - September 20, 2017
UK HTA body NICE has decided to make Bristol-Myers Squibb's PD-1 inhibitor Opdivo available for non-small-cell lung cancer, but only...
The Pink Sheet - September 20, 2017
European CHMP Opinions And MAA Updates
A monthly-updated listing of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization...
The Pink Sheet - September 20, 2017
A monthly-updated listing of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization...
The Pink Sheet - September 20, 2017
Real-World Evidence Requires 'Leap Of Faith' For Industry, FDA – Gottlieb
US FDA Commissioner says agency will soon offer more clarity on using real-world evidence in drug development, but notes industry...
The Pink Sheet - September 20, 2017
US FDA Commissioner says agency will soon offer more clarity on using real-world evidence in drug development, but notes industry...
The Pink Sheet - September 20, 2017
US FDA's Benefit/Risk Framework Gets High Marks But Could Be Improved
Agency summaries contained in reviews of novel drugs and biologics are useful and informative but difficult to find, and their...
The Pink Sheet - September 20, 2017
Agency summaries contained in reviews of novel drugs and biologics are useful and informative but difficult to find, and their...
The Pink Sheet - September 20, 2017
Unsuccessful IPOs
Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences...
IN VIVO - September 20, 2017
Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences...
IN VIVO - September 20, 2017
Amazon Versus Biotech: How The IPO Class Of '97 Worked Out
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16...
IN VIVO - September 20, 2017
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16...
IN VIVO - September 20, 2017
Number To Know…63 million
Emergent BioSolutions has won a $63m contract to develop an antidote spray device treating known or suspected acute cyanide poisoning.
Medtech Insight - September 20, 2017
Emergent BioSolutions has won a $63m contract to develop an antidote spray device treating known or suspected acute cyanide poisoning.
Medtech Insight - September 20, 2017
GMP, Claim And Label Warning Follows Firm's Ephedra Recall
FDA Office of Regulatory Affairs' warning letter to MusclMasster lists 12 separate violations of supplement GMP regulations. Puerto Rico firm...
The Rose Sheet - September 19, 2017
FDA Office of Regulatory Affairs' warning letter to MusclMasster lists 12 separate violations of supplement GMP regulations. Puerto Rico firm...
The Rose Sheet - September 19, 2017
Cosmetic Ingredient Review Report Status
Chart: Data compiled by the Rose Sheet from information in CIR reports following the Expert Panel's Sept. 11-12 meeting.
The Rose Sheet - September 19, 2017
Chart: Data compiled by the Rose Sheet from information in CIR reports following the Expert Panel's Sept. 11-12 meeting.
The Rose Sheet - September 19, 2017
CIR News In Brief: No Conclusion Reached On PHMB; Endocrine Activity Guidance; More
At its Sept. 11-12 meeting in Washington, the Cosmetic Ingredient Review Expert Panel finalized reports for various protein and peptide...
The Rose Sheet - September 19, 2017
At its Sept. 11-12 meeting in Washington, the Cosmetic Ingredient Review Expert Panel finalized reports for various protein and peptide...
The Rose Sheet - September 19, 2017
Nut Ingredient Listeria Contamination Leads To More Protein Bar Recalls
Health Warrior, ISS One and Amrita brand proteins made with HVF-supplied nut ingredients are class I recalls.
The Rose Sheet - September 19, 2017
Health Warrior, ISS One and Amrita brand proteins made with HVF-supplied nut ingredients are class I recalls.
The Rose Sheet - September 19, 2017